Dubai, United Arab Emirates:– In a joint effort to accelerate the UAE’s vision for a world-class healthcare system, the Dubai Branch of BD (Becton, Dickinson and Company) (NYSE: BDX), and VPS Healthcare’s Burjeel Medical City (BMC) today announced a strategic partnership that will enable both organizations to accelerate innovation and deliver healthcare excellence in the country.
“This partnership is a cornerstone of our combined efforts to help advance UAE’s healthcare system,” said Maher Elhassan, Vice President & General Manager, BD Middle East, North Africa & Turkey. “The continued emphasis on patient safety inspires us to invest more into innovative collaborations to deliver safety and care to both patients and healthcare workers, rapid diagnosis, antimicrobial resistance as well as training of medical practitioners. Together, we will advance the world of health and positively impact patient lives.”
The collaboration between BD and Burjeel Medcial City will create valuable opportunities to offer the healthcare provider with cutting-edge MedTech innovations in pursuit of offering improved safety and care for patients and healthcare workers in the UAE. In addition to medtech solutions, this joint effort will enhance safety practices and measures through providing trainings to enable a better understanding of advanced solutions and safety procedures.
Speaking about the partnership, John Sunil, CEO, Burjeel Group stated “As a leading healthcare network in UAE, we understand how laboratories play a vital role in delivering patient care. The Burjeel Medical City’s Central Lab is equipped with total lab automation, allowing us to connect all our sites across the U.A.E. with a capacity of nearly 10 million tests per year.
Our collaboration with BD is yet another important step in our pursuit of constantly delivering healthcare excellence and improving patient outcomes. This partnership will enable us to detect emerging antimicrobial resistance, rapidly implement infection control procedures, initiate appropriate antibiotic therapies for treating these infections and improving patient management .
Burjeel Medical City is constantly investing and establishing new partnerships to identify cutting-edge medical technologies and innovations that can help us deliver world-class healthcare to the people of the UAE.”
The partnership will also explore new ways to boost improvement in rapid diagnosis while reducing errors in the course of treatments. As part of the training, BD and Burjeel Medical City will also work on creating awareness of antimicrobial resistance (AMR) procedures. This will lead to decreasing the risks of infections and maintaining adequate prevention against prolonged illness, timely and accurate diagnostics, surveillance and advanced medication management.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.